



IMPORTANT NEWS FROM: [GENTA \(GNTA\)](#), [SAMARITAN PHARMACEUTICALS \(LIV\)](#), [ALFACEL \(\(ACEL\)](#)

CANCER

Colon

Genta ([GNTA](#) - [news](#)) Genasense, Genta's antisense drug, seems to enhance radiation therapy in colon cancer. The combination of Genasense plus radiation demonstrated a significant delay in tumor growth in animals whose tumors over-expressed Bcl-2. Genasense had no effect on tumors that did not express Bcl-2; moreover, a reverse-sequence compound was also ineffective. These findings indicate that the observed effects were specific for both the Bcl-2 target as well as the Genasense sequence. **Read more:** [New Experimental Results Show Genasense\(R\) Enhances Radiation Therapy in Colon Cancer](#)

Lung

Alfacell Corporation ([ACEL-news](#)) today announced that Intae Lee, Ph.D., Department of Radiology, University of Pennsylvania, is presenting new data on the effectiveness of **ONCONASE®** (ranpirnase) **against non-small cell lung cancer (NSCLC)** at the 47th Annual Meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO), held on October 16-20 in Denver. Dr. Lee's presentation is entitled, 'The Enhanced Efficacy Of Cisplatin And Carboplatin By The RNase ONCONASE® On A549 Human Lung Cancer Xenografts Of Nude Mice.' Read more: [New ONCONASE\(R\) Non-Small Cell Lung Cancer Data Presented at ASTRO Annual Meeting](#)

ALZHEIMER'S DISEASE

Samaritan Pharmaceuticals ([LIV](#) - [news](#)) a developer of innovative drugs, announced that a manuscript describing its "Alzheimer's Rat Model", a tool which enables researchers to create an Alzheimer's disease-like profile in rats, and test new Alzheimer's drugs, will be published in the Journal Pharmacology (2006, vol. 76, pages 19-33). A pre-publication print of the manuscript entitled "Beta-Amyloid and Oxidative Stress Jointly Induce Neuronal Death, Amyloid Deposits, Gliosis, and Memory Impairment" **Read more:** [New Breakthrough Invention Hopes to Pave the Way to Innovative Novel Treatments for Alzheimer's Disease](#)

PROHOST RESEARCH
P.O. BOX 640 429
Oakland Gardens, Ny 11364
Telephone : 516 678 1335
Fax 718 423 2731
E-mail prohost@aol.com.

FORWARD-LOOKING STATEMENT Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: <http://www.sec.gov/consumer/cyberfr.htm>